Tavolixizumab

Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research[1].

Product Specifications

CAS Number

[1635395-25-3]

Product Name Alternative

MEDI 0562; Tavolimab

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tavolixizumab.html

Purity

99.76

Solubility

10 mM in DMSO

Smiles

[Tavolixizumab]

Molecular Weight

(146.36 kDa)

References & Citations

[1]Claudia Giampietri, et al. Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies. J Transl Med. 2022 Oct 12;20 (1) :467.